This unique ground-breaking work, authored by renowned Harvard-based researchers G I Papakostas and M Fava, represents, by far, the most comprehensive compilation to date of medical studies and reports involving the use of antidepressants for the treatment of major depressive di…
1. Major depressive disorder and treatment-resistant depression. 1.1. Major depressive disorder. 1.2. Treatment-resistant depression (TRD). 1.3. Demographic and clinical risk factors for resistant depression -- 2. Monoaminergic-based strategies : "Single-acting" agents. 2.1. Mon…
This unique and ground-breaking work, authored by renowned Harvard-and Massachusetts General Hospital based researchers G. I. Papakostas and M. Fava, represents the most comprehensive compilation to date of medical studies and reports involving the use of antidepressants for the…
This unique ground-breaking work, authored by renowned Harvard-based researchers G I Papakostas and M Fava, represents, by far, the most comprehensive compilation to date of medical studies and reports involving the use of anti-depressants for the treatment of major depressive d…
Twenty-five years after Prozac entered the marketplace, 10 percent of Americans over the age of six use an SSRI antidepressant. Sharpe explores questions of identity that arise for people who start medication before they have an adult sense of self. She asks why some individuals…
When Katherine Sharpe arrived at her college health center with an age-old complaint, a bad case of homesickness, she received a thoroughly modern response: a twenty-minute appointment and a prescription for Zoloft'a drug she would take for the next ten years. This outcome, once…
Twenty-five years after Prozac entered the marketplace, 10 percent of Americans over the age of six use an SSRI antidepressant. Sharpe explores questions of identity that arise for people who start medication before they have an adult sense of self. She asks why some individuals…
